1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Since 2021, shares of (NASDAQ: NVAX) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the past few years. The price drop was justified largely because the company's fate was uncertain. There were question marks relating to its growth and a canceled purchase agreement.
The good news is that one of those issues recently reached a positive resolution. Is that enough to make this beaten-down stock worth taking a chance on?
One of the clouds hanging over Novavax was a dispute with a global vaccine organization called Gavi, the Vaccine Alliance. The issue goes back to 2022 when Novavax terminated a purchase agreement with Gavi after it didn't procure the doses it had previously agreed to buy. Gavi paid $700 million in advance, which it ended up wanting a refund for as the shots weren't needed anymore. But Novavax said the payments were nonrefundable.
Source Fool.com
Novavax Inc. Stock
With 7 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 26 € shows a very positive potential of 82.02% compared to the current price of 14.28 € for Novavax Inc..
